Prestige Consumer Healthcare (NYSE:PBH) Cut to Hold at StockNews.com

StockNews.com lowered shares of Prestige Consumer Healthcare (NYSE:PBH) from a buy rating to a hold rating in a report released on Monday morning.

Other equities research analysts have also issued research reports about the stock. DA Davidson increased their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a report on Monday, December 9th. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Canaccord Genuity Group increased their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Finally, Oppenheimer raised their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $92.60.

Prestige Consumer Healthcare Price Performance

Shares of Prestige Consumer Healthcare stock opened at $82.83 on Monday. The business’s fifty day moving average price is $81.22 and its 200 day moving average price is $78.12. Prestige Consumer Healthcare has a twelve month low of $62.35 and a twelve month high of $90.04. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $4.10 billion, a P/E ratio of 19.40, a PEG ratio of 2.69 and a beta of 0.46.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, research analysts anticipate that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Insider Transactions at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. US Bancorp DE raised its stake in shares of Prestige Consumer Healthcare by 20.3% in the 3rd quarter. US Bancorp DE now owns 3,978 shares of the company’s stock valued at $287,000 after purchasing an additional 672 shares in the last quarter. Covestor Ltd raised its stake in Prestige Consumer Healthcare by 95.6% during the third quarter. Covestor Ltd now owns 1,338 shares of the company’s stock valued at $96,000 after buying an additional 654 shares in the last quarter. Meritage Portfolio Management raised its stake in Prestige Consumer Healthcare by 11.0% during the third quarter. Meritage Portfolio Management now owns 11,992 shares of the company’s stock valued at $865,000 after buying an additional 1,193 shares in the last quarter. Aigen Investment Management LP acquired a new position in shares of Prestige Consumer Healthcare in the 3rd quarter worth approximately $345,000. Finally, MQS Management LLC acquired a new position in shares of Prestige Consumer Healthcare in the 3rd quarter worth approximately $552,000. 99.95% of the stock is currently owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.